1814 related articles for article (PubMed ID: 25980751)
21. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
[TBL] [Abstract][Full Text] [Related]
22. [Inhibition of growth and metastasis of hepatocellular carcinoma by rapamycin: experiment with mice].
Wang Z; Fan J; Zhou J; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1666-70. PubMed ID: 16854316
[TBL] [Abstract][Full Text] [Related]
23. Vigilin is overexpressed in hepatocellular carcinoma and is required for HCC cell proliferation and tumor growth.
Yang WL; Wei L; Huang WQ; Li R; Shen WY; Liu JY; Xu JM; Li B; Qin Y
Oncol Rep; 2014 May; 31(5):2328-34. PubMed ID: 24676454
[TBL] [Abstract][Full Text] [Related]
24. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T
Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613
[TBL] [Abstract][Full Text] [Related]
25. Celastrus orbiculatus Extracts Inhibit Human Hepatocellular Carcinoma Growth by Targeting mTOR Signaling Pathways.
Qian YY; Li WY; Yan Y; Zhao XY; Yang T; Fang CC; Hou JJ; Liu YQ
Chin J Integr Med; 2019 Nov; 25(11):845-852. PubMed ID: 31127506
[TBL] [Abstract][Full Text] [Related]
26. NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth.
Zha X; Hu Z; Ji S; Jin F; Jiang K; Li C; Zhao P; Tu Z; Chen X; Di L; Zhou H; Zhang H
Cancer Lett; 2015 Apr; 359(1):97-106. PubMed ID: 25578782
[TBL] [Abstract][Full Text] [Related]
27. Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC.
Gandhy SU; Imanirad P; Jin UH; Nair V; Hedrick E; Cheng Y; Corton JC; Kim K; Safe S
Oncotarget; 2015 Sep; 6(28):26359-72. PubMed ID: 26317792
[TBL] [Abstract][Full Text] [Related]
28. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
[TBL] [Abstract][Full Text] [Related]
30. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo.
Jia XQ; Cheng HQ; Li H; Zhu Y; Li YH; Feng ZQ; Zhang JP
Chin Med J (Engl); 2011 Nov; 124(22):3794-9. PubMed ID: 22340243
[TBL] [Abstract][Full Text] [Related]
32. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.
Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC
Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
Zhou M; Zhang XY; Yu X
Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
[TBL] [Abstract][Full Text] [Related]
35. Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice.
Xiao CL; Tao ZH; Guo L; Li WW; Wan JL; Sun HC; Wang L; Tang ZY; Fan J; Wu WZ
BMC Cancer; 2011 Apr; 11():150. PubMed ID: 21513518
[TBL] [Abstract][Full Text] [Related]
36. GP73 promotes epithelial-mesenchymal transition and invasion partly by activating TGF-β1/Smad2 signaling in hepatocellular carcinoma.
Yang Y; Liu Q; Li Z; Zhang R; Jia C; Yang Z; Zhao H; Ya S; Mao R; Ailijiang T; Bao Y; Zhang H
Carcinogenesis; 2018 Jul; 39(7):900-910. PubMed ID: 29365054
[TBL] [Abstract][Full Text] [Related]
37. Nuclear α1-antichymotrypsin promotes chromatin condensation and inhibits proliferation of human hepatocellular carcinoma cells.
Santamaria M; Pardo-Saganta A; Alvarez-Asiain L; Di Scala M; Qian C; Prieto J; Avila MA
Gastroenterology; 2013 Apr; 144(4):818-828.e4. PubMed ID: 23295442
[TBL] [Abstract][Full Text] [Related]
38. microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis.
Roy S; Hooiveld GJ; Seehawer M; Caruso S; Heinzmann F; Schneider AT; Frank AK; Cardenas DV; Sonntag R; Luedde M; Trautwein C; Stein I; Pikarsky E; Loosen S; Tacke F; Ringelhan M; Avsaroglu SK; Goga A; Buendia MA; Vucur M; Heikenwalder M; Zucman-Rossi J; Zender L; Roderburg C; Luedde T
Gastroenterology; 2018 Dec; 155(6):1951-1966.e26. PubMed ID: 30165047
[TBL] [Abstract][Full Text] [Related]
39. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
[TBL] [Abstract][Full Text] [Related]
40. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
